Exemptia contains Adalimumab, a monoclonal antibody that belongs to the class of tumor necrosis factor-alpha (TNF-α) inhibitors. It is used to treat autoimmune and inflammatory disorders by targeting and neutralizing TNF-α, a protein involved in inflammation. Exemptia is typically administered as a subcutaneous injection.

Mechanism of Action

• Adalimumab binds specifically to TNF-α, preventing it from interacting with its receptors on cell surfaces.

• This inhibits the inflammatory cascade, reducing inflammation, swelling, and tissue damage.

• By controlling TNF-α activity, it helps manage chronic autoimmune conditions and prevents disease progression.

  Uses

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Ankylosing spondylitis

  • Plaque psoriasis

  • Crohn’s disease and ulcerative colitis

  • Can be used in combination with methotrexate for enhanced effect in certain conditions.

    Adverse Effects

    • Injection site reactions (redness, swelling, pain)

    • Upper respiratory infections (cold, sinus infections)

    • Headache

    • Mild nausea